Home About Us Services ↳ Canada PR Visa (Permanent Residency) ↳ Work Permit Canada ↳ LMIA — Labour Market Impact Assessment ↳ Spouse & Family Sponsorship Visa ↳ Student Visa Canada ↳ Visitor Visa ↳ Business Visa Provinces ↳ 🏙️ Ontario ↳ 🏔️ British Columbia ↳ 🌾 Alberta ↳ 🌻 Saskatchewan ↳ 🌊 Manitoba ↳ ⚓ Nova Scotia ↳ 🍁 New Brunswick ↳ 🦞 Prince Edward Island ↳ 🐟 Newfoundland & Labrador ↳ 🌊 Atlantic Immigration Program Healthcare Blog FAQ Careers Canadian Latest policies Contact

Notice: Revision of Guidance documents: Conduct and Analysis of Comparative Bioavailability Studies & Comparative Bioavailability Standards: Formulations used for Systemic Effects

June 8, 2018
Our file number: 18-104623-884

Health Canada is pleased to announce the revision of two guidance documents, entitled Conduct and Analysis of Comparative Bioavailability Studies and Comparative Bioavailability Standards: Formulations used for Systemic Effects.

Changes to the documents in this revision include removal of guidance on the use of urine data for bioequivalence assessment and inclusion of guidance on highly variable drug products and multiphasic modified release drug products.

The Notice: Policy on Bioequivalence Standards for Highly Variable Drug Products (April 18, 2016) will be superseded by these guidances when they come into effect. A draft of the section on multiphasic modified release drug products was released for consultation in July 2017. Stakeholder comments on this section have been considered in this revision. These comments together with responses from the Therapeutic Products Directorate have been collated in a separate document, which is available upon request. Requests for this document should be directed to the email address below.

These guidance documents will come into effect for submissions filed on or after September 1, 2018.

Any reduced requirements articulated in these two guidance documents would apply immediately should an application be filed prior to September 1, 2018.

Questions or concerns in this regard or related to the Guidance Documents: Conduct and Analysis of Comparative Bioavailability Studies and Comparative Bioavailability Standards: Formulations used for Systemic Effects should be directed to:

Bureau of Policy, Science and International Programs
Therapeutic Products Directorate
Health Canada
1600 Scott Street
Holland Cross, Tower B
2nd Floor, Address Locator 3102C5
Ottawa, Ontario
K1A 0K9

Telephone: 613-948-4623
Facsimile: 613-941-1812
E-mail: hc.policy.bureau.enquiries.sc@canada.ca

Page details

2018-06-12

Quick Enquiry

We usually reply within a few hours
By submitting you agree to be contacted about your enquiry.
Call us Chat on WhatsApp
M

Migova AI Assistant

Online now
Hi 👋 I'm the Migova AI assistant, powered by OpenAI. Ask me about PR, study visas, work permits, LMIA, family sponsorship, provinces, or healthcare immigration to Canada.
Canada PR
Study Visa
LMIA / Work Permit